Anti- FcRH5/IRTA2/CD307e Antibody (Cevostamab)
Catalog No.
F1306
Anti- FcRH5/IRTA2/CD307e Antibody (Cevostamab)
Featured Products
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based BsAb that targets the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. In addition, Cevostamab promotes the formation of effective synapses and enhances the cytotoxic activity of T cells against MM tumor cells.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
/
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
BFCR4350A, RO-7187797, RG6160
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q96RD9
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human IRTA2 His at 2 ug/mL can bind Anti- FcRH5/IRTA2/CD307e Antibody (Cevostamab)
FcRH5 / IRTA2 / CD307e
Please avoid freeze-thaw cycles.